These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 1132045

  • 1. [On the article of J. Buchanec and V. Kdrajnák: Lesions of the liver during therapy with erythromycin in 3 children].
    Rouzica M, Filipová K.
    Cesk Pediatr; 1975 Jan; 30(1-2):71. PubMed ID: 1132045
    [No Abstract] [Full Text] [Related]

  • 2. Erythromycin estolate-induced hepatitis. Ultrastructural study of liver.
    Gafter U, Mandel EM, Weiss S, Djaldetti M.
    N Y State J Med; 1979 Jan; 79(1):87-9. PubMed ID: 282477
    [No Abstract] [Full Text] [Related]

  • 3. FDA begins proceedings to remove erythromycin estolate from market.
    FDA Drug Bull; 1979 Nov; 9(5):26-7. PubMed ID: 510836
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Cholestatic hepatitis caused by erythromycin estolate].
    García Monzón C, Noguerado A, Hidalgo S, Escudero V.
    Rev Clin Esp; 1985 Nov; 177(8):420-1. PubMed ID: 3836470
    [No Abstract] [Full Text] [Related]

  • 6. Erythromycin propionate and estolate.
    Farre M.
    Lancet; 1988 Jul 02; 2(8601):45. PubMed ID: 2898648
    [No Abstract] [Full Text] [Related]

  • 7. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate.
    Keeffe EB, Reis TC, Berland JE.
    Dig Dis Sci; 1982 Aug 02; 27(8):701-4. PubMed ID: 6980110
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Controlled study of the liver-protective effect of cycloxilic acid in a form of iatrogenic liver disease].
    Neuman M, Fluteau G.
    Clin Ter; 1978 Nov 15; 87(3):243-64. PubMed ID: 380876
    [No Abstract] [Full Text] [Related]

  • 11. Hepatotoxicity of erythromycin derivatives.
    Pessayre D, Benhamou JP.
    Br Med J; 1979 May 19; 1(6174):1357. PubMed ID: 445081
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Case study: Drug interference in clinical chemistry.
    Hansen JL, Swanson LN.
    Am J Med Technol; 1981 Mar 19; 47(3):189-91. PubMed ID: 7223765
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Hepatotoxicity from erythromycin estolate].
    Saiz Santos S, Montero López L.
    Aten Primaria; 1992 Dec 19; 10(9):1050. PubMed ID: 1467424
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Erythromycin-induced hepatitis].
    Perrier M, Portier G, de Calan L, Favre JP, Ozoux JP, Rivallain B, Brizon J.
    Cah Anesthesiol; 1987 Dec 19; 35(3):237. PubMed ID: 3621021
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Erythromycin estolate hepatotoxicity.
    Lloyd-Still JD, Sherman JO, Boggs J, Demers LM.
    Am J Dis Child; 1978 Mar 19; 132(3):320. PubMed ID: 629252
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.